gantenerumab

Home
Ligands
gantenerumab

GtoPdb Ligand ID: 6933

Synonyms: R-1450 | RG-1450 | Ro-4909832

Comment: Gantenerumab targets aggregated forms of human amyloid β (Aβ) proteins Aβ42 and Aβ40. This is in contrast to solanezumab which targets soluble Aβ.
Annotated peptide sequences for this antibody are available from its IMGT/mAb-DB record.
Protein sequence analysis reveals that gantenerumab is likely to be clone #7.9.H7 in patent US7794719 [1].

No information available.

No information available.

Summary of Clinical Use
Proposed to be useful in the treatment of Alzheimer's disease [3]. In phase 1 trials treatment caused reduced brain amyloid β levels, but was associated with the unwanted side effect of vasogenic edema. Clinical development of gantenerumab was discontinued at phase 3 phase 3.

Summary of Clinical Use

Proposed to be useful in the treatment of Alzheimer's disease [3]. In phase 1 trials treatment caused reduced brain amyloid β levels, but was associated with the unwanted side effect of vasogenic edema. Clinical development of gantenerumab was discontinued at phase 3 phase 3.

Clinical Trials
Clinical Trial ID	Title	Type	Source	Comment	References
NCT01760005	Dominantly Inherited Alzheimer Network Trial: An Opportunity to Prevent Dementia. A Study of Potential Disease Modifying Treatments in Individuals at Risk for or With a Type of Early Onset Alzheimer's Disease Caused by a Genetic Mutation.	Phase 2/Phase 3 Interventional	Washington University School of Medicine